Description:

Sorafenib is a targeted anticancer medication used to treat certain types of cancers, including:

• Unresectable hepatocellular carcinoma (liver cancer)

• Advanced renal cell carcinoma (kidney cancer)

• Differentiated thyroid carcinoma that is refractory to radioactive iodine treatment​

It functions as a multikinase inhibitor, blocking specific proteins that promote cancer cell growth and angiogenesis.

Prescription:

• Prescription-only medication.​

Dosage:

The recommended dosage is 400 mg orally twice daily without food (at least 1 hour before or 2 hours after a meal).

Therapeutic Category:

• Antineoplastic agent – Tyrosine kinase inhibitor.​

Active Ingredients/Composition:

• Active Ingredient: Sorafenib tosylate (equivalent to 200 mg of sorafenib per tablet).​

Variant:

• Film-coated oral tablet.​

Consume Type:

• Oral administration.​

Directions/Usage:

• Take 400 mg twice daily on an empty stomach (at least 1 hour before or 2 hours after a meal).

• Swallow tablets whole with water; do not crush, chew, or split.

• If a dose is missed, skip it and resume the next dose at the regular time. Do not double the dose.

• Continue treatment as prescribed unless advised otherwise by your healthcare provider.

Common Side Effects:

• Diarrhea

• Rash and skin reactions (including hand-foot skin reaction)

• Fatigue

• Hair thinning or loss

• Nausea and vomiting

• Hypertension (high blood pressure)

• Bleeding

• Loss of appetite ​

Package Type:

• Typically supplied in bottles containing 112 tablets (200 mg each).​

Storage Advice:

• Store at room temperature (20°C to 25°C or 68°F to 77°F).

• Protect from moisture and light.

• Keep out of reach of children.​

Safety Advice:

• Not recommended during pregnancy; may cause fetal harm.

• Avoid breastfeeding during treatment and for at least 2 weeks after the last dose.

• Use with caution in patients with cardiovascular conditions or bleeding disorders.

• Inform your healthcare provider of all medications and supplements you are taking to avoid potential interactions.

Product Substitutes:

• Generic versions of sorafenib may be available.

• Alternative tyrosine kinase inhibitors (e.g., lenvatinib, sunitinib) may be considered based on the specific cancer type and patient condition.​

Manufacturer/Marketer:

• Nexavar

• Manufacturer: Bayer HealthCare Pharmaceuticals Inc

Country of Origin:

• United States